TITLE: Vancomycin-Resistant Enterococci Isolation and Screening Strategies: Clinical Evidence and Cost-Effectiveness

DATE: 10 March 2014

RESEARCH QUESTIONS

1. What is the clinical evidence regarding the effectiveness of patient isolation for vancomycin-resistant enterococci (VRE)-producing organisms?

2. What is the clinical evidence regarding the impact of isolation on patients isolated for VRE colonization?

3. What is the clinical evidence on the effectiveness of screening strategies for VRE?

4. What is the cost-effectiveness of patient screening and isolation for VRE?

KEY MESSAGE

One randomized controlled trial, one non-randomized study, and one economic evaluation were identified regarding either the clinical or cost-effectiveness of patient screening or isolation measures for VRE.

METHODS

A limited literature search was conducted on key resources including PubMed, Medline, The Cochrane Library (2014, Issue 3), University of York Centre for Reviews and Dissemination (CRD) databases, ECRI (Health Devices Gold), Canadian and major international health technology agencies, as well as a focused Internet search. No methodological filters were applied to limit retrieval by publication type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2012 and March 3, 2014. Internet links were provided, where available.
RESULTS

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials, non-randomized studies, and economic evaluations.

One randomized controlled trial, one non-randomized study, and one economic evaluation were identified regarding either the clinical or cost-effectiveness of patient screening or isolation measures for VRE. No health technology assessments, systematic reviews, or meta-analyses were identified.

Additional references of potential interest are provided in the appendix.

Health Technology Assessments
No literature identified.

Systematic Reviews and Meta-analyses
No literature identified.

Randomized Controlled Trials


Non-Randomized Studies


Economic Evaluations


PREPARED BY:
Canadian Agency for Drugs and Technologies in Health
Tel: 1-866-898-8439
www.cadth.ca
APPENDIX – FURTHER INFORMATION:

Systematic Reviews and Meta-analyses – General Control and Prevention


Non-Randomized Studies

Patient-Days Used for Isolation


Case Control


Review Article


Additional References

Rapid Response Reports

8. Discontinuation of contact precautions for antibiotic resistant organisms: clinical evidence and guidelines [Internet]. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2013 Jan 24. [cited 2014 Mar 6]. Available from: http://www.cadth.ca/media/pdf/htis/jan-2013/RA0612%20Discontinuation%20of%20Contact%20Precautions%20Final.pdf

Other


